tbuckley/cabot-search huggingface dataset:
10. Cardiovascular Disease and Risk Management: <i>Standards of Care in Diabetes—2024</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Sandeep R. Das, Laya Ekhlaspour, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Mikhail N. Kosiborod, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, Robert A. Gabbay
Journal: Diabetes Care (2023)

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
16. Diabetes Care in the Hospital: <i>Standards of Care in Diabetes—2024</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Rodolfo J. Galindo, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, Robert A. Gabbay
Journal: Diabetes Care (2023)

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Summary of Revisions: <i>Standards of Care in Diabetes—2024</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Elizabeth A. Beverly, Dennis Bruemmer, Billy S. Collins, Kenneth Cusi, Audrey Darville, Sandeep R. Das, Laya Ekhlaspour, Talya K. Fleming, Jason L. Gaglia, Rodolfo J. Galindo, Christopher H. Gibbons, John M. Giurini, Mohamed Hassanein, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Mikhail N. Kosiborod, Robert F. Kushner, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Lisa Murdock, Nicola Napoli, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Elizabeth Selvin, Paolo S. Silva, Robert C. Stanton, Monica Verduzco-Gutierrez, Crystal C. Woodward, Zobair M. Younossi, Robert A. Gabbay
Journal: Diabetes Care (2023)
15. Management of Diabetes in Pregnancy: <i>Standards of Care in Diabetes—2024</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, Robert A. Gabbay
Journal: Diabetes Care (2023)

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
7. Diabetes Technology: <i>Standards of Care in Diabetes—2024</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, Robert A. Gabbay
Journal: Diabetes Care (2023)

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
3. Prevention or Delay of Diabetes and Associated Comorbidities: <i>Standards of Care in Diabetes—2024</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Jason L. Gaglia, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Elizabeth Selvin, Robert C. Stanton, Robert A. Gabbay
Journal: Diabetes Care (2023)

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity
Authors: Yining Zhu, Jingyao Ma, Ruochen Shen, Jinghan Lin, Shuyi Li, Xiaoya Lu, Jessica L. Stelzel, Jiayuan Kong, Leonardo Cheng, Ivan Vuong, Zhi-Cheng Yao, Christine Wei, Nicole M. Korinetz, Wu Han Toh, Joseph Choy, Rebekah A. Reynolds, Melanie J. Shears, Won June Cho, Natalie K. Livingston, Gregory P. Howard, Yizong Hu, Stephany Y. Tzeng, Donald J. Zack, Jordan J. Green, Lei Zheng, Joshua C. Doloff, Jonathan P. Schneck, Sashank K. Reddy, Sean C. Murphy, Hai-Quan Mao
Journal: Nature Biomedical Engineering (2023)
Genetic architecture of cardiac dynamic flow volumes
Authors: Bruna Gomes, Aditya Singh, Jack W. O’Sullivan, Theresia M. Schnurr, Pagé C. Goddard, Shaun Loong, David Amar, J. Weston Hughes, Mykhailo Kostur, Francois Haddad, Michael Salerno, Roger Foo, Stephen B. Montgomery, Victoria N. Parikh, Benjamin Meder, Euan A. Ashley
Journal: Nature Genetics (2023)
Origin and evolution of the triploid cultivated banana genome
Authors: Xiuxiu Li, Sheng Yu, Zhihao Cheng, Xiaojun Chang, Yingzi Yun, Mengwei Jiang, Xuequn Chen, Xiaohui Wen, Hua Li, Wenjun Zhu, Shiyao Xu, Yanbing Xu, Xianjun Wang, Chen Zhang, Qiong Wu, Jin Hu, Zhenguo Lin, Jean-Marc Aury, Yves Van de Peer, Zonghua Wang, Xiaofan Zhou, Jihua Wang, Peitao Lü, Liangsheng Zhang
Journal: Nature Genetics (2023)
Macroscopic resting-state brain dynamics are best described by linear models
Authors: Erfan Nozari, Maxwell A. Bertolero, Jennifer Stiso, Lorenzo Caciagli, Eli J. Cornblath, Xiaosong He, Arun S. Mahadevan, George J. Pappas, Dani S. Bassett
Journal: Nature Biomedical Engineering (2023)

It is typically assumed that large networks of neurons exhibit a large repertoire of nonlinear behaviours. Here we challenge this assumption by leveraging mathematical models derived from measurements of local field potentials via intracranial electroencephalography and of whole-brain blood-oxygen-level-dependent brain activity via functional magnetic resonance imaging. We used state-of-the-art linear and nonlinear families of models to describe spontaneous resting-state activity of 700 participants in the Human Connectome Project and 122 participants in the Restoring Active Memory project. We found that linear autoregressive models provide the best fit across both data types and three performance metrics: predictive power, computational complexity and the extent of the residual dynamics unexplained by the model. To explain this observation, we show that microscopic nonlinear dynamics can be counteracted or masked by four factors associated with macroscopic dynamics: averaging over space and over time, which are inherent to aggregated macroscopic brain activity, and observation noise and limited data samples, which stem from technological limitations. We therefore argue that easier-to-interpret linear models can faithfully describe macroscopic brain dynamics during resting-state conditions.
Associations between Short-Term Exposure to Ambient Air Pollution and Influenza: An Individual-Level Case-Crossover Study in Guangzhou, China
Authors: Rong Zhang, Ka Yan Lai, Wenhui Liu, Yanhui Liu, Xiaowei Ma, Chris Webster, Lei Luo, Chinmoy Sarkar
Journal: Environmental Health Perspectives (2023)

Influenza imposes a heavy burden on public health. Little is known, however, of the associations between detailed measures of exposure to ambient air pollution and influenza at an individual level.
Acute ischemia induces spatially and transcriptionally distinct microglial subclusters
Authors: Huiya Li, Pinyi Liu, Bing Zhang, Zengqiang Yuan, Mengdi Guo, Xinxin Zou, Yi Qian, Shiji Deng, Liwen Zhu, Xiang Cao, Tao Tao, Shengnan Xia, Xinyu Bao, Yun Xu
Journal: Genome Medicine (2023)

Abstract Background Damage in the ischemic core and penumbra after stroke affects patient prognosis. Microglia immediately respond to ischemic insult and initiate immune inflammation, playing an important role in the cellular injury after stroke. However, the microglial heterogeneity and the mechanisms involved remain unclear. Methods We first performed single-cell RNA-sequencing (scRNA-seq) and spatial transcriptomics (ST) on middle cerebral artery occlusion (MCAO) mice from three time points to determine stroke-associated microglial subclusters and their spatial distributions. Furthermore, the expression of microglial subcluster-specific marker genes and the localization of different microglial subclusters were verified on MCAO mice through RNAscope and immunofluorescence. Gene set variation analysis (GSVA) was performed to reveal functional characteristics of microglia sub-clusters. Additionally, ingenuity pathway analysis (IPA) was used to explore upstream regulators of microglial subclusters, which was confirmed by immunofluorescence, RT-qPCR, shRNA-mediated knockdown, and targeted metabolomics. Finally, the infarct size, neurological deficits, and neuronal apoptosis were evaluated in MCAO mice after manipulation of specific microglial subcluster. Results We discovered stroke-associated microglial subclusters in the brains of MCAO mice. We also identified novel marker genes of these microglial subclusters and defined these cells as ischemic core-associated (ICAM) and ischemic penumbra-associated (IPAM) microglia, according to their spatial distribution. ICAM, induced by damage-associated molecular patterns, are probably fueled by glycolysis, and exhibit increased pro-inflammatory cytokines and chemokines production. BACH1 is a key transcription factor driving ICAM generation. In contrast, glucocorticoids, which are enriched in the penumbra, likely trigger IPAM formation, which are presumably powered by the citrate cycle and oxidative phosphorylation and are characterized by moderate pro-inflammatory responses, inflammation-alleviating metabolic features, and myelinotrophic properties. Conclusions ICAM could induce excessive neuroinflammation, aggravating brain injury, whereas IPAM probably exhibit neuroprotective features, which could be essential for the homeostasis and survival of cells in the penumbra. Our findings provide a biological basis for targeting specific microglial subclusters as a potential therapeutic strategy for ischemic stroke.
Microfluidics‐Prepared Ultra‐small Biomimetic Nanovesicles for Brain Tumor Targeting
Authors: Ji Wang, Xiaoxi Ma, Zhihao Wu, Binbin Cui, Changbin Zou, Pengfei Zhang, Shuhuai Yao
Journal: Advanced Healthcare Materials (2023)

Blood-brain-barrier (BBB) serves as a fatal guard of the central nervous system as well as a formidable obstacle for the treatment of brain diseases such as brain tumors. Cell membrane-derived nanomedicines are promising drug carriers to achieve BBB-penetrating and brain lesion targeting. However, the challenge of precise size control of such nanomedicines has severely limited their therapeutic effect and clinical application in brain diseases. To address this problem, this work develops a microfluidic mixing platform that enables the fabrication of cell membrane-derived nanovesicles with precise controllability and tunability in particle size and component. Sub-100 nm macrophage plasma membrane-derived vesicles as small as 51 nm (nanoscale macrophage vesicles, NMVs), with a narrow size distribution (polydispersity index, PDI: 0.27) and a high drug loading rate (up to 89% for indocyanine green-loaded NMVs, NMVs@ICG (ICG is indocyanine green)), are achieved through a one-step process. Compared to beyond-100 nm macrophage cell membrane vesicles (general macrophage vesicles, GMVs) prepared via the traditional methods, the new NMVs exhibits rapid (within 1 h post-injection) and enhanced orthotopic glioma targeting (up to 78% enhancement), with no extra surface modification. This work demonstrates the great potential of such real-nanoscale cell membrane-derived nanomedicines in targeted brain tumor theranostics.
SQANTI-SIM: a simulator of controlled transcript novelty for lrRNA-seq benchmark
Authors: Jorge Mestre-Tomás, Tianyuan Liu, Francisco Pardo-Palacios, Ana Conesa
Journal: Genome biology (2023)

Long-read RNA sequencing has emerged as a powerful tool for transcript discovery, even in well-annotated organisms. However, assessing the accuracy of different methods in identifying annotated and novel transcripts remains a challenge. Here, we present SQANTI-SIM, a versatile tool that wraps around popular long-read simulators to allow precise management of transcript novelty based on the structural categories defined by SQANTI3. By selectively excluding specific transcripts from the reference dataset, SQANTI-SIM effectively emulates scenarios involving unannotated transcripts. Furthermore, the tool provides customizable features and supports the simulation of additional types of data, representing the first multi-omics simulation tool for the lrRNA-seq field.
Apoferritin‐Cu(II) Nanoparticles Induce Oncosis in Multidrug‐Resistant Colon Cancer Cells
Authors: Kai Xiong, Xinlin Lin, Junfeng Kou, Fangmian Wei, Jinchao Shen, Yu Chen, Liangnian Ji, Hui Chao
Journal: Advanced Healthcare Materials (2023)

Abstract Multidrug resistance (MDR) limits the application of clinical chemotherapeutic drugs. There is an urgent need to develop non‐apoptosis‐inducing agents that circumvent drug resistance. Herein, four therapeutic copper complexes encapsulated in natural nanocarrier apoferritin (AFt‐Cu1‐4) are reported. Although they are isomers, they exhibit significantly different organelle distributions and cell death mechanisms. AFt‐Cu1 and AFt‐Cu3 accumulate in the cytoplasm and induce autophagy, whereas AFt‐Cu2 and AFt‐Cu4 can quickly enter the nucleus and trigger oncosis. Excitedly, AFt‐Cu2 and AFt‐Cu4 show a strong tumor growth inhibition effect in mice models bearing multidrug‐resistant colon xenograft via intravenous injection. To the best of the authors’ knowledge, this is the first example of metal‐based nucleus‐targeted oncosis inducers overcoming multidrug resistance in vivo.
Acupuncture for primary insomnia: Effectiveness, safety, mechanisms and recommendations for clinical practice
Authors: Fei-Yi Zhao, Sarah J. Spencer, Gerard A. Kennedy, Zhen Zheng, Russell Conduit, Wen-Jing Zhang, Peijie Xu, Li-Ping Yue, Yan-Mei Wang, Yan Xu, Qiang-Qiang Fu, Yuen-Shan Ho
Journal: Sleep Medicine Reviews (2023)
Differential molecular profiles and associated functionalities characterize connective tissue grafts obtained at different locations and depths in the human palate
Authors: Maria B. Asparuhova, Xiaoqing Song, Dominic Riedwyl, Geert van Geest, Dieter D. Bosshardt, Anton Sculean
Journal: International Journal of Oral Science (2023)

Abstract The present study aimed to assess the molecular profiles of subepithelial connective tissue grafts (CTGs) obtained at different locations and depths in the human palate. Sixty-four CTGs belonging to anterior deep (AD), anterior superficial (AS), posterior deep (PD), and posterior superficial (PS) groups were subjected to RNA-Sequencing and their transcriptomes were analyzed computationally. Functional correlations characterizing the CTG groups were validated by cell biological experiments using primary human palatal fibroblasts (HPFs) extracted from the CTGs. A clearly more pronounced location-dependent than depth-dependent difference between the grafts, with a minimal number of genes (4) showing no dependence on the location, was revealed. Epithelial, endothelial, and monocytic cell migration was strongly ( P &lt; 0.001) potentiated by AD- and PS-HPFs. Moreover, significantly increased expression of genes encoding C-C and C-X-C motif chemokine ligands as well as significantly ( P &lt; 0.01) activated p38 signaling suggested immunomodulatory phenotype for AD- and PS-HPFs. Increased growth factor gene expression and significantly activated ( P &lt; 0.001) Erk and Akt signaling in HPFs originating from A-CTGs implied their involvement in cell survival, proliferation, and motility. Prominent collagen-rich expression profile contributing to high mechanical stability, increased osteogenesis-related gene expression, and strongly activated ( P &lt; 0.001) Smad1/5/8 signaling characterized HPFs originating from P-CTGs. The present data indicate that in humans, differences between palatal CTGs harvested from different locations and depths appear to be location- rather than depth-dependent. Our findings provide the basis for future personalization of the therapeutic strategy by selecting an optimal graft type depending on the clinical indications.
Heterogeneous Treatment Effects of Intensive Glycemic Control on Kidney Microvascular Outcomes and Mortality in ACCORD
Authors: Vivek Charu, Jane W. Liang, Glenn M. Chertow, June Li, Maria E. Montez-Rath, Pascal Geldsetzer, Ian H. de Boer, Lu Tian, Manjula Kurella Tamura
Journal: Journal of the American Society of Nephrology (2023)

Significance Statement Identifying and quantifying treatment effect variation across patients is the fundamental challenge of precision medicine. Here we quantify heterogeneous treatment effects of intensive glycemic control in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, considering three outcomes of interest—a composite kidney outcome (driven by macroalbuminuria), all-cause mortality, and first assisted hypoglycemic event. We demonstrate that the effects of intensive glycemic control vary with risk of kidney failure, as predicted by the kidney failure risk equation (KFRE). Participants at highest risk of kidney failure gain the largest absolute kidney benefit of intensive glycemic control but also experience the largest absolute risk of death and hypoglycemic events. Our findings illustrate the value of identifying clinically meaningful treatment heterogeneity, particularly when treatments have different effects on multiple end points. Objective Clear criteria to individualize glycemic targets in patients with type II diabetes are lacking. In this post hoc analysis of the ACCORD, we evaluate whether the KFRE can identify patients for whom intensive glycemic control confers more benefit in preventing kidney microvascular outcomes. Research Design and Methods We divided the ACCORD trial population into quartiles on the basis of 5-year kidney failure risk using the KFRE. We estimated conditional treatment effects within each quartile and compared them with the average treatment effect in the trial. The treatment effects of interest were the 7-year restricted mean survival time (RMST) differences between intensive and standard glycemic control arms on ( 1 ) time-to-first development of severely elevated albuminuria or kidney failure and ( 2 ) all-cause mortality. Results We found evidence that the effect of intensive glycemic control on kidney microvascular outcomes and all-cause mortality varies with baseline risk of kidney failure. Patients with elevated baseline risk of kidney failure derived the most from intensive glycemic control in reducing kidney microvascular outcomes (7-year RMST difference of 114.8 [95% confidence interval 58.1 to 176.4] versus 48.4 [25.3 to 69.6] days in the entire trial population) However, this same patient group also experienced a shorter time to death (7-year RMST difference of −56.7 [−100.2 to −17.5] v. −23.6 [−42.2 to −6.6] days). Conclusions We found evidence of heterogenous treatment effects of intensive glycemic control on kidney microvascular outcomes in ACCORD as a function of predicted baseline risk of kidney failure. Patients with higher kidney failure risk experienced the most pronounced reduction in kidney microvascular outcomes but also experienced the highest risk of all-cause mortality.